

US EPA ARCHIVE DOCUMENT



OPP OFFICIAL RECORD  
HEALTH EFFECTS DIVISION  
SCIENTIFIC DATA REVIEWS  
EPA SERIES 361

CASWELL FILE

125601 19

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

JUN 29 1988

OFFICE OF  
PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM

SUBJECT: <sup>a</sup> Paclobutrazol, Use of the CULTAR 2SC Formulation  
for the Dermal Absorption Study

TO: Robert Taylor PM-25  
Registration Division (TS-767)

FROM: Robert P. Zendzian PhD  
Senior Pharmacologist  
Toxicology Branch  
HED (TS-769)

6/29/88

THROUGH: William Burnam  
Deputy Chief  
Toxicology Branch

WB  
6/29/88

Compound; Paclobutrazol	Tox Chem #628C
Registration #7G3524	Registrant; ICI
Accession #N/A	Tox Project #8-0767

Action Requested

The Registrant is planning a dermal absorption of paclobutrazol utilizing the CULTAR 2SC formulation as the basic test material and requests Agency approval of the test material.

Response and recommendation

The agency protocol for dermal absorption recommends using the use formulation for the high dose and dilutions of same in the field solvent, usually water, for lower doses. Since dermal absorption of a compound is dependent on the properties of the compound and the solvent in which it is applied, this approach allows a more realistic evaluation of dermal penetration of the active ingredient under use conditions. Considering the Agency identified risk, <sup>14</sup>C-paclobutrazol in the CULTAR 2SC formulation is the appropriate test material for the high dose. This material should be diluted with the field solvent for lower doses.

1/